Vitreomacular interface diseases: Diagnosis and management  by Levison, Ashleigh L. & Kaiser, Peter K.
lable at ScienceDirect
Taiwan Journal of Ophthalmology 4 (2014) 63e68Contents lists avaiTaiwan Journal of Ophthalmology
journal homepage: www.e-t jo.comReview articleVitreomacular interface diseases: Diagnosis and management
Ashleigh L. Levison, Peter K. Kaiser*
Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USAa r t i c l e i n f o
Article history:
Received 25 November 2013
Accepted 4 December 2013
Available online 13 January 2014
Keywords:
epiretinal membrane
lamellar hole
macular hole
pseudohole
vitreomacular adhesion
vitreomacular interface disorders
vitreomacular tractionConﬂicts of interest: Peter K. Kaiser is a cons
Thrombogenics, and Allegro.
* Corresponding author. Cole Eye Institute, Clevel
Euclid Avenue i-13, Cleveland, OH 44195, USA.
E-mail address: pkkaiser@gmail.com (P.K. Kaiser).
2211-5056/$ e see front matter Copyright  2013, Th
http://dx.doi.org/10.1016/j.tjo.2013.12.001a b s t r a c t
This article discusses the diagnosis and management of abnormal vitreomacular interfaces disorders
including vitreomacular adhesion, vitreomacular traction, epiretinal membrane, full thickness macular
holes, lamellar holes and pseudoholes. Optical coherence tomography has better enabled our ability to
diagnose abnormalities of the vitreoretinal interface by providing clinical information that cannot be
obtained by other ophthalmic diagnostic techniques. While vitrectomy remains the most commonly
performed treatment for these disorders, the recent introduction of pharmacologic vitreolysis represents
the development of non-surgical treatment options of certain diseases of the vitreoretinal interface.
Copyright  2013, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
The vitreous ﬁlls the space between the lens and the ciliary body
anteriorly and the lens and the retina posteriorly. The vitreous
comprises approximately 80% of the volume of the eye. It is
composed of approximately 98% water and 2% proteins and an
extracellular matrix. Collagen is themajor structural protein; type II
collagen and type IX collagen are the most common proteins, and
make up 75% and 15%, respectively, of the collagen in the vitre-
ous.1,2 The vitreous also contains hyaluronan, chondroitin sulfate,
ﬁbrillins, and opticin.
The strongest points of attachment of the vitreous to the retina
are at the optic nerve, macula, ora serrata, and around the blood
vessels.3 The equatorial and posterior vitreoretinal interfaces
consist of the posterior vitreous cortex, the internal limiting
membrane (ILM), and the intervening extracellular matrix.1 The
ILM is primarily composed of type IV collagen. The posterior vit-
reous cortex and retinal ILM are bound at their interface by this
macromolecular attachment complex, which is composed of
ﬁbronectin, laminin, and other extracellular components that form
a glue-like matrix. Chondroitin sulfate is present at this interface
and has an important role in the strong vitreoretinal interface.1ultant for Alcon, Novartis,
and Clinic Foundation, 9500
e Ophthalmologic Society of TaiwThe normal aging process of the vitreous gel causes the
development of posterior vitreous detachment (PVD). Liquefac-
tion of the vitreous occurs over time, thereby creating lacunae or
pockets in the vitreous.1 Synchysis (i.e., the process of vitreous gel
liquefaction) ﬁrst begins at approximately the age of 4 years.2
Vitreoretinal separation normally occurs at many sites
throughout the peripheral fundus. This process occurs for years
prior to a ﬁnal separation of the vitreous from the macula and
optic nerve occurs and leads to PVD. The early stages are typically
asymptomatic.4 Posterior vitreous detachment normally results in
a complete and clean separation between the ILM of the retina and
the cortical vitreous.5
An anomalous separation of the vitreous cortex from the ILM
can lead to an abnormal vitreoretinal interface. This separation can
happenwhen liquefaction occurs faster than the detachment of the
vitreous cortex or when an abnormal adhesion of the vitreous
cortex to the ILM occurs.6 Various pathologic vitreomacular inter-
face diseases can develop when there is an anomalous PVD.7
Most abnormal vitreomacular interface diseases were histori-
cally diagnosed by slit lamp biomicroscopy with or without the
addition of ﬂuorescein angiography. Thus, many subtle alterations
to the vitreomacular interface were often missed clinically. The
introduction of optical coherence tomography (OCT) approximately
two decades ago has dramatically altered the ability to diagnose
abnormalities of the vitreoretinal interface by providing clinical
information that cannot be obtained by other ophthalmic diag-
nostic techniques. In 2004, the development of spectral domain
OCT, which has increased resolution and more rapid scanningan. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Disorders of the vitreoretinal interface. (A) Vitreomacular adhesion, which is
adhesion of the vitreous at the fovea without distortion of the retinal contour. (B)
Vitreomacular traction, which is abnormal vitreous adhesion with excessive traction of
the fovea that causes pseudocyst formation. (C) Full-thickness macular hole, which is a
full-thickness retinal defect with posterior vitreous detachment. (D) Epiretinal mem-
brane, which has cellular proliferation on the surface of the inner retina that creates
traction and loss of the foveal contour. (E) Lamellar hole, which is a partial-thickness
foveal defect with an irregular foveal contour and a splitting of the inner and outer
retina. (F) Pseudohole, which is an epiretinal membrane with a central opening that
causes a steep macular contour at the central fovea.
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vitreomacular interface with better consistency and accuracy.8
In this manuscript, we will explore the diagnosis and manage-
ment of abnormal vitreomacular interfaces diseases such as vitre-
omacular adhesion (VMA), vitreomacular traction (VMT), epiretinal
membrane (ERM), full-thickness macular holes (FTMH), and
lamellar holes and pseudoholes (Fig. 1).2. Vitreomacular adhesion
The diagnosis of VMA is applied to patients who have incom-
plete separation of the posterior vitreous with persistent attach-
ment to the macula. This term has been broadly used to include
patients with and without distortion of the retinal architecture;
however, the term should only be used for patients who have an
intact retinal architecture. In the past, VMA has been classiﬁed by
symptomatic patients versus asymptomatic patients (i.e., based on
a patient’s visual complaints). With the introduction of OCT, phy-
sicians have become aware that VMA is amore common entity than
was previously clinically known and may be part of the normal
formation of PVD.9
A group of retina specialists, the International Vitreomacular
Traction Study (IVTS) Group, recently deﬁned the OCT character-
istics of VMA.5 The IVTS new deﬁnition of VMA is more restrictive
than the deﬁnition previously used. On OCT, VMA is a speciﬁc
stage of vitreous separation when partial detachment of the vit-
reous in the perifoveal area has occurred without any abnormal-
ities to the retinal contour. The slit lamp examination is clinically
normal. Eyes with VMA are subclassiﬁed by the size of the adhe-
sion. An adhesion is either focal (i.e., less than 1500 mm) or broad
(i.e., greater than 1500 mm). Focal points of dehiscence between
the vitreous and retina can be present within areas of broad VMA.5
Vitreomacular adhesion is typically asymptomatic and non-
pathologic, and does not cause any apparent retinal changes.10 It is
a natural component of the development of a PVD and can
therefore be considered an incomplete PVD.9,11 Vitreomacular
adhesion, although asymptomatic, has been hypothesized as
playing a role in the pathogenesis of many macular conditions
such as neovascular age-related macular degeneration, macular
hole, and diabetic macular edema.9
Based on the new characterization of VMA deﬁned by the Inter-
national Vitreomacular Traction StudyGroup, VMA is a normal stage
in the process of PVD, is not associated with symptoms, and causes
no change in the retinal architecture. Treatment is not required.
These patients should be observed for resolution or for the pro-
gression to vitreomacular traction or, possibly, a macular hole.5
3. Vitreomacular traction
In certain patients with abnormal vitreous adhesion, there can
be excessive traction on the macula from the vitreous that changes
the contour of the foveal surface. Findings on slit lamp bio-
microscopy may be subtle, but there may be a distortion of the
fovea, a blunted foveal reﬂex, cystic changes, or (in severe cases)
subretinal ﬂuid. Optical coherence tomography allows the direct
visualization of the vitreoretinal interface; therefore, very subtle
distortion of the foveal contour on OCTmay be the only feature that
distinguishes VMT from focal VMA when the retinal anatomy is
otherwise normal.10 In addition, there may be elevation of the
retina at the fovea at the level of the retinal pigment epithelium
(RPE). The combination of anatomical changes on OCT with signs of
perifoveolar PVD constitutes a diagnosis of VMT.5 In accordance
with the International Vitreomacular Traction Study Group deﬁni-
tion, VMT (like VMA) can be classiﬁed as “focal” or “broad”, based
on the horizontal width of the adhesion. These broad areas of
attachment with traction can be associated with thickening of the
macula, vascular leakage on ﬂuorescein angiography, macular
schisis, and cystoid macular edema.5 The anatomical changes to the
fovea induced by VMT can lead to reduced visual acuity,9 meta-
morphopsia, and micropsia.8
The natural history of patients with VMT is not well established.
John et al9 performed a consecutive case series evaluating the
clinical course of what they referred to as “vitreomacular
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included in their study would have various levels of severity of
vitreomacular traction. The IVTS deﬁned Grade 1 as incomplete
separation of the cortical vitreous with persistent vitreous attach-
ment at the fovea and ILM. In the study by John et al,9 eyes at Grade
1 did show evidence of abnormal foveal contour. They deﬁned
Grade 2 as eyes with the features of Grade 1 and either a intra-
retinal cyst, cleft, or schisis; and they deﬁned Grade 3 as eyes with
the features of Grade 2 and subretinal ﬂuid resulting from neuro-
sensory elevation of the retina from the retinal pigment epithe-
lium.9 At the end of their study, overall 32% of eyes had
spontaneously resolved, including eyes from all grades. The dif-
ference in the resolution rates between the various grades was not
statistically signiﬁcant. The rate of a clinically worsening anatomy
was also the same among the three grades. John et al9 concluded
that an initial observation period is a reasonable option for patients
with at least milder forms of vitreomacular traction.
The standard treatment for severe vitreomacular traction is pars
plana vitrectomy. The goal of vitreous surgery is to eliminate
anteroposterior and tangential traction, thereby relieving the
attachment of the vitreous to the macula. The visual acuity out-
comes are mixed for pars plana vitrectomy for vitreomacular
traction. Various studies have reported visual acuity improvement
in approximately 44e78% of patients; vision improvement was
limited by cystoid macular edema, ﬁbrosis, chronic retinal
detachment, and macular schisis.12,13 A recently published sys-
tematic review found that only approximately one-third of eyes
gained two lines on the Snellen chart.14 Visual acuity may not
improve, although metamorphopsia often does improve.
Vitreoretinal surgery has risks such as bleeding, infection,
retinal detachment, cataract development, and anesthesia risks. A
meta-analysis of pars plana vitrectomy for vitreomacular traction
reported that intraoperative retinal tears occur in 1.6% of eyes and
postoperative retinal detachment occurs in 4.6% of eyes.14 There-
fore, nonsurgical treatment of VMT with pharmacological
vitreolysis has important implications for the treatment of vitre-
omacular traction.3 In October 2012, the medication ocriplasmin
(Jetrea; ThromboGenics, Leuven, Belgium and Alcon, Basel,
Switzerland) received FDA approval for the treatment of symp-
tomatic VMA. Ocriplasmin is a recombinant human serine protease
plasmin with proteolytic activity against several target proteins
(e.g., laminin, ﬁbronectin, and collagen) in the vitreous and vitre-
oretinal interface. The protease activity induces vitreous liquefac-
tion and the separation of the vitreous from the retina, thereby
creating PVD and releasing the vitreous traction.15,16
The Microplasmin Intravitreal InjectioneTraction Release
without Surgical Treatment (MIVI-TRUST) Study Group conducted
two multicenter, randomized, double-blinded Phase 3 clinical trials
to compare an intravitreal injection of ocriplasmin with a placebo
injection in patients with symptomatic VMA, which included VMA
associated with a full-thickness macular hole.17 The MIVI-TRUST
group found that ocriplasmin can resolve VMT, induce PVD, and
cause the anatomic closure of nearly 40% of macular holes. The
study included 652 eyes, 464 of which received ocriplasmin and
188 of which received placebo. The VMA resolved in 26.5% of eyes
treated with ocriplasmin, compared to 10.1% of the placebo-treated
eyes. Total PVD occurred in 13.4% of ocriplasmin eyes, compared to
3.7% of eyes treated with a placebo. Women, phakic patients, and
patients without an ERM more often met the endpoint at 28 days,
compared to their counterparts.17
Two interventions are now available for vitreomacular traction:
pars plana vitrectomy and pharmacologic vitreolysis. The risks and
beneﬁts, appropriate ﬁt for treatment, and rate of treatment suc-
cess should be consideredwhen determining the best treatment for
individual patients.4. Full-thickness macular hole
A full-thickness macular hole (FTMH) is a full thickness defect in
the fovea, and includes the complete interruption of all neural
retinal layers from the ILM to the retinal pigment epithelium.
Anteroposterior traction, secondary to abnormal vitreoretinal
attachment at the fovea, and tangential contraction of the peri-
foveal vitreous cortex may be responsible for the development of
macular holes.18
Vitreoretinal specialists have classically diagnosed idiopathic
FTMHs by using slit lamp biomicroscopy. It clinically appears as an
eccentric oval, crescent, or central round retinal defect at the fovea.
Gass’ clinical classiﬁcation scheme has long been the standard for
classifying macular holes. A stage 1 hole represents a partial
thickness macular hole, whereas a stage 2 macular hole is a FTMH
that is less than 400microns; a stage 3 macular hole corresponds to
a central round defect exceeding 400 microns but without com-
plete PVD. A FTMH in the setting of a complete PVD is a stage 4
macular hole, regardless of the diameter of the retinal defect.19,20
The Gass classiﬁcation is commonly used in clinical practice;
however, OCT images now further add to our understanding of
macular holes. The International Vitreomacular Traction Study
Group has developed an OCT-based anatomic classiﬁcation system
for FTMHs. The criteria are based on the size of the hole, the status
of the vitreous, and on whether the etiology of the macular hole is
primary or secondary. The minimum hole width is measured at the
narrowest point in the mid-retina. This can be measured by using
the caliper function of the OCT machine. Macular holes less than
250 microns are classiﬁed as small; holes 250e400 microns are
classiﬁed as medium; and holes greater than 400 microns are
classiﬁed as large.5 The second and third components of the new
IVTS classiﬁcation system are the presence or absence of vitreous
attachment on OCT and the etiology of the macular hole (i.e., pri-
mary or secondary). A primary macular hole is commonly referred
to as an idiopathic macular hole. These are caused by vitreous
traction on the fovea from an abnormal vitreous separation. A
secondary macular hole is caused by other pathologies not associ-
ated with previous VMT. Examples include blunt trauma, high
myopia, macular telangiectasia type 2, surgical trauma, and other
causes of macular edema.
Prior to the introduction of ocriplasmin in 2012, there were only
two options available for the management of macular holes:
observation and surgical intervention with vitrectomy. In 1991,
surgery was introduced for FTMHs.21 Pars plana vitrectomy is
performed with or without ILM peeling. In 2013, a Cochrane review
was published that examined the literature regarding the effec-
tiveness of ILM peeling.22 The analysis indicated that more patients
in the ILM peeling group had primary macular hole closure with an
odds ratio of 9.27 and a 95% conﬁdence interval (CI) of 4.98e17.24.
However, there was no difference in the primary outcome of dis-
tance visual acuity at 6months or 12months after surgery. The ﬁnal
conclusion of the meta-analysis was that ILM peeling was possibly
more cost effective because of the higher likelihood of primary
closure and decreased likelihood of having to return to the oper-
ating room for further surgery.22
If the decision is made to peel the ILM, dyes that stain the ILM
are commonly used to differentiate the ILM from underlying retinal
layers. The most commonly used vital dye in the United States is
indocyanine green (ICG).23 On light exposure, ICG increases the
stiffness of the ILM, thereby easing the peeling of the ILM. However,
the use of ICG is not without risk and has been associated with
toxicity, which causes RPE damage, visual ﬁeld defects, and possible
optic nerve atrophy.24 Surgeons must avoid excessive light expo-
sure because it is potentially toxic; in addition, surgeons should not
hold the illumination instruments close to the retina.23 Brilliant
A.L. Levison, P.K. Kaiser / Taiwan Journal of Ophthalmology 4 (2014) 63e6866Blue has also been used to stain the ILM; however, ICG remains the
most consistently used agent by vitreoretinal surgeons.25,26
Gas tamponade is typically used after vitrectomy for macular
hole closure. Options include air, sulfur hexaﬂuoride (SF6), and
perﬂuoropropane (C3F8). Thompson et al27 reported a 97% closure
rate with C3F8 and a 53% closure rate with air. In their study there
was no statistically signiﬁcant difference between 20% SF6 gas and
16% C3F8 gas in the closure rate, regardless of the stage or duration
of symptoms.27 In general, physicians recommend using short-
acting gases such as SF6 for small and medium holes (i.e., <400
microns) and long-lasting gases such as C3F8 for large holes (i.e.,
>400 microns).
Face-down positioning is a key component of postoperative care
after macular hole surgery. In 2011, a Cochrane review was pub-
lished that evaluated the role of positioning in macular hole repair.
Only three randomized control trials were identiﬁed. A meta-
analysis was not possible because of the heterogeneity of the
duration of face-down positioning. However, each of the studies
showed no beneﬁt to face-down positioning for holes less than 400
microns. For holes larger than 400 microns, face-down positioning
effectively aided hole closure after vitrectomy.28 Most surgeons
continue to use face-down positioning, regardless of the hole size.
Pharmacologic vitreolysis is a new nonsurgical option that can
aid closure of macular holes that are associated with vitreomacular
traction. The treatment degrades the macromolecular vitreous
attachment complex and relieves the tractional forces that caused
the foveal lesion. In theMIVI-TRUST study patients with FTMHs less
than 400 microns in width, the closure of the holes occurred in
40.6% of ocriplasmin-treated eyes and 10.6% of placebo-treated
eyes.15,17 In patients with small holes, the success rate was even
higher. This occurred without face-down positioning, surgery, or a
gas bubble. This makes it an appealing option for the appropriate
patients.17
5. Epiretinal membrane
The epiretinal membrane (ERM) is a cellular proliferation that
creates a semitranslucent, ﬁbrocellular proliferation on the surface
of the inner retina. Because ERMs contain contractile cellular ele-
ments, they can be associated with retinal folding and macular
thickening, thereby leading to decreased visual acuity, meta-
morphopsia, micropsia, and monocular diplopia. Most epiretinal
membranes can be detected clinically on slit lamp examination.
They appear as a reﬂective sheen over the retina and cause wrin-
kling of the retinal surface. An ERM can progressively becomemore
opaque, thereby obscuring retinal details and leading to intraretinal
ﬂuid accumulation.1
Epiretinal membranes affect approximately seven percent of the
population and are bilateral in 10e20% of patients.29 In the Blue
Mountain Eye Study, the 5-year incidence of ERMs was 5.3%.29
Epiretinal membranes are idiopathic if they occur in otherwise
healthy eyes. In idiopathic cases of ERM, cellular proliferation may
be associated with an incomplete PVD.30 Epiretinal membranes can
also arise secondary to retinal vascular disease, diabetes, trauma,
inﬂammatory conditions, tumors, and retinal dystrophies.
Slit lamp biomicroscopy and ﬂuorescein angiography histori-
cally have been used to evaluate epiretinal membranes. Because of
the introduction of OCT, ﬂuorescein angiography is no longer per-
formed, unless evaluating the etiology of the ERM such as branch
retinal vein occlusion. On OCT, ERMs appear as a hyper-reﬂective
layer on the surface of the inner retina. Epiretinal membranes
may cause distortion of the retinal surface, blunting of the foveal
contour, and pseudocyst formation.1
Time-domain OCT was an important tool for the diagnosis of
epiretinal membranes; however, with the development of spectraldomain OCT, physicians are better able to evaluate the predictors of
outcomes after surgery. Cobos et al31 showed the integrity of the
inner segment/outer segment junction is essential for improving
visual acuity after surgically removing the ERM. Several factors
(e.g., preoperative visual acuity, duration of the symptoms prior to
surgery, and the presence or absence of cystoid macular edema)
have been suggested as prognostic factors that inﬂuence post-
operative visual acuity.32
If visual acuity is only mildly reduced, ERMs are typically
observed. In patients with ERM, vision is less than 20/70 in only 15%
of patients. Wiznia et al33 showed no further decrease in visual
acuity in 87% of 47 eyes during 2e4 years of follow-up. If there is a
severe reduction in visual acuity, the standard surgical approach
includes a pars plana vitrectomy and peeling of the epiretinal
membrane. Some surgeons also peel the ILM in an attempt to pre-
vent reproliferation of the membrane.30 The overall rate of recur-
renceof idiopathic ERMis reportedlyup to21%. Peeling the ILM is the
only reported factor in preventing recurrence.34 Sandali et al35 re-
ported a lower rate of recurrence at 5%, but consistently found that
ILM peeling was the only factor that prevented ERM recurrence.6. Lamellar holes
In 1975, Gass described a lamellar hole as a macular lesion
resulting from cystoid macular edema.36 A lamellar macular hole
(LMH) is now known as a partial thickness foveal defect; however,
there is no universally accepted deﬁnition of lamellar macular
holes. On slit lamp biomicroscopy, lamellar holes typically appear
as a round or oval, reddish lesion. The introduction of OCT has
greatly improved the ability to diagnose a LMH.37 In studies by
Haouchine et al38 and Witkin et al,39 only 28% and 37%, respec-
tively, of LMH cases diagnosed by OCT examination were clinically
detected on fundus examination. Witkin et al39 used OCT ﬁndings
to create a formal deﬁnition of a lamellar macular hole. These
include an irregular foveal contour, a defect or break in the inner
fovea, a splitting of the inner and outer retina, lack of a full-
thickness foveal defect, and intact photoreceptors.39 The Interna-
tional Vitreomacular Traction Study Group included this deﬁnition
in their recent categorization of lamellar macular holes.5
Lamellarmacular holes are typically accompanied by complaints
ofmild central vision loss andmetamorphopsia.5 Many believe they
arise from incomplete full-thickness macular hole formation.5 Epi-
retinal membranes are commonly associated with eyes that have
lamellar macular holes. The pathogenesis, conﬁguration, and pro-
gression of lamellar macular holes are therefore believed to be
affected by tangential retinal traction due to ERM contraction.37
Lamellar macular holes are most often present because most
patients with a lamellar macular hole only have a mild reduction in
visual acuity and mild metamorphopsia; rarely do these symptoms
progress to signiﬁcant vision loss.40 Theodossiadis et al41 found that
visual acuity was stable in approximately 80% of patients during a
follow-up period of 37.1months. Bottoni et al42 had similar ﬁndings
in that patients had stable visual acuity for more than 18 months.
Lamellar macular holes that present with progressive thinning
of foveal thickness and decreased visual acuity may beneﬁt from
vitrectomy.42 Duker et al5 reviewed the literature and found that,
after surgery for lamellar macular holes, the rate of visual acuity
improvement ranged 25e75% and was typically because of epi-
retinal membrane peeling. There are no prospective studies
examining pars plana vitrectomy for lamellar macular holes. Rei-
baldi et al36 found that preservation of the External limiting
membrane (ELM) on OCT appears to be important in the potential
preservation of visual acuity. Most clinicians believe that surgical
treatment of lamellar macular holes is unproven.43
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On slit lamp biomicroscopy, a macular pseudohole clinically
appears as a discrete, reddish, round or oval lesion in the fovea that
is typically 200e400 microns in diameter and similar in appear-
ance to a small or medium-sized FTMH. Pseudoholes are caused by
contraction of the ERM and have been reported in 8e20% of eyes
with ERM.44
Optical coherence tomography better detects the anatomic
changes at the vitreomacular interface that leads to a macular
pseudohole. Of most importance is that pseudoholes have no loss of
retinal tissue. They have an invaginated or heaped foveal edge, an
ERM with a central opening, and a steep macular contour to the
central fovea. The steep foveal contour creates the appearance of a
hole, even though there is no true loss of retinal tissue. It may be
that the absence or loss of foveal tissue is responsible for the better
visual acuity in eyes with pseudoholes, compared to eyes with
lamellar holes.45
The natural history of pseudoholes suggests that good visual
acuity can be maintained for a long period.45 If the ERM is the cause
of the decreased vision, then pars plana vitrectomywithmembrane
peel is an option. Restoration of a normal foveal contour can lead to
some improvement in vision.5 Massin et al44 examined 50 eyes that
underwent vitrectomy for ERM with pseudoholes and compared
them to eyes with ERM without pseudoholes. Massin44 found that
the preoperative and the postoperative visual acuity differed
signiﬁcantly between the group with pseudoholes and the group
without pseudoholes.44 In addition, the presence of a pseudohole
did not suggest a poor prognosis. Pseudoholes are typically
observed, unless there is a signiﬁcant reduction in vision.
8. Conclusion
In summary, a variety of diseases of the vitreoretinal interface
exists. Optical coherence tomography has allowed physicians to
describe, classify, and understand better the vitreoretinal interface
and the abnormalities that can develop. Vitrectomy remains the
most commonly performed treatment for the various interface
disorders, but the recent introduction of pharmacologic vitreolysis
represents a movement towards developing nonsurgical treatment
options for certain diseases of the vitreoretinal interface.
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